OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+47.65%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$600M
AUM Growth
+$600M
(+37%)
Cap. Flow
+$6.02M
Cap. Flow
% of AUM
1%
Top 10 Holdings %
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13
Top Buys
| 1 |
Arvinas
ARVN
|
$17.2M |
| 2 |
Codexis
CDXS
|
$16.4M |
| 3 |
Liquidia Corp
LQDA
|
$13.7M |
| 4 |
Ginkgo Bioworks
DNA
|
$6.68M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$3.56M |
Top Sells
| 1 |
Catalyst Pharmaceutical
CPRX
|
$10.5M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$7.26M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$7.19M |
| 4 |
Cytokinetics
CYTK
|
$6.5M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.88M |
Sector Composition
| 1 | Healthcare | 98.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Iovance Biotherapeutics
IOVA
$800M
| – | – |
-897,000
| Closed | -$7.19M |
|
52
Fulcrum Therapeutics
FULC
$353M
| – | – |
-285,000
| Closed | -$1.77M |
|
|
53
4D Molecular Therapeutics
FDMT
$302M
| – | – |
-345,750
| Closed | -$7.26M |
|
54
Design Therapeutics
DSGN
$339M
| – | – |
-205,000
| Closed | -$687K |
|
55
Aligos Therapeutics
ALGS
$75.1M
| – | – |
-1,260,000
| Closed | -$441K |
|